Search results for "Portal"

Imaging-guided interventions modulating portal venous flow: Evidence and controversies

2021

Portal hypertension is defined by an increase in the portosystemic venous gradient. In most cases, increased resistance to portal blood flow is the initial cause of elevated portal pressure. More than 90% of cases of portal hypertension are estimated to be due to advanced chronic liver disease or cirrhosis. Transjugular intrahepatic portosystemic shunts, a non-pharmacological treatment for portal hypertension, involve the placement of a stent between the portal vein and the hepatic vein or inferior vena cava which helps bypass hepatic resistance. Portal hypertension may also be a result of extrahepatic portal vein thrombosis or compression. In these cases, percutaneous portal vein recanalis…

Heart rate variability is associated with disease severity and portal hypertension in cirrhosis

2023

Introduction: Autonomic nervous system activity in cirrhotic portal hypertension is linked to hyperdynamic circulation. Heart rate variability (HRV) is a validated noninvasive method to assess the sympathovagal balance. To investigate the correlation between HRV parameters and degree of portal hypertension, we studied a cohort of patients with cirrhosis accounting for etiology and treatments. Patients and Methods: In this cross-sectional, observational cohort study, 157 outpatients of both sex with nonalcoholic cirrhosis were assessed by upper gastrointestinal endoscopy to search for esophagogastric varices. Twenty-four-hour electrocardiogram Holter monitoring with 3 HRV parameters measurem…

"Table 44" of "Search for long-lived particles produced in $pp$ collisions at $\sqrt{s}=13$ TeV that decay into displaced hadronic jets in the ATLAS …

2018

Endcap MS vertex efficiencies (in %) for baryogenesis $\chi \rightarrow \tau\tau\nu$ benchmark samples ($m_{h}=125$ GeV). The vertex reconstruction efficiency is defined as the fraction of simulated LLP decays in the MS fiducial volume that match a reconstructed vertex ($\Delta R(\textrm{LLP,vertex}) = 0.4$) passing the baseline event selection and satisfying the vertex isolation criteria. A vertex is considered matched to a displaced decay if the vertex is within $\Delta R = 0.4$ of the simulated decay position. The MS vertex efficiency is parameterized as a function of the LLP decay position.

IL PORTALE ITALIANO DELLE MALATTIE COMPLESSE: UNO STRUMENTO PER L’EMPOWERMENT DI CITTADINI E LA FORMAZIONE DEI MEDICI.

2014

Comparison of two different techniques of reperfusion in adult orthotopic liver transplantation

2006

: The aim of this study was to determine the impact of two reperfusion techniques on the peri-operative hemodynamic changes and early post-operative graft function of adult patients undergoing orthotopic liver transplantation. Material and methods: From June 2003 to May 2004, 50 consecutive liver transplants were performed and divided into two groups: group A, 25 patients, portal vein flush with 500 cm3 of Ringer's lactate without vena caval venting. Group B, 25 patients, vena caval venting with no portal vein flush. Donor and recipient characteristics were similar in both groups. Sixty-four different parameters were analyzed, and Pearson's χ2 test and t-test were used for statistical analy…

Another Small Step Forward in ALPPS

2020

Enterprise Portal Personalization: Direct and Indirect End-User Effects, and the Moderating Effects of Gender

2009

Enterprise portals offer rich functionality for end- user personalization, but few studies have been conducted on the end-user effects of this feature. This article presents a study of end-user effects of personalization, using the combined technology acceptance model (TAM) and the theory of planned behaviour (TPB) as a research framework. We propose that personalization indirectly affects end-users' intentions through effects on ease of use, usefulness, attitude and behaviour control. In addition, it may have a direct effect on end-users' intentions to use enterprise portals that is not mediated by the variables of the combined TAM/TPB-model. Because previous studies have found gender diff…

Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients

2019

IF 4.5; International audience; Background & AimsThe quantification of lipopolysaccharide (LPS) in biological fluids is challenging. We aimed to measure plasma LPS concentration using a new method of direct quantification of 3‐hydroxymyristate (3‐HM), a lipid component of LPS, and to evaluate correlations between 3‐HM and markers of liver function, endothelial activation, portal hypertension and enterocyte damage.MethodsPlasma from 90 noninfected cirrhotic patients (30 Child‐Pugh [CP]‐A, 30 CP‐B, 30 CP‐C) was prospectively collected. The concentration of 3‐HM was determined by high‐performance liquid chromatography coupled with mass spectrometry.Results3‐HM levels were higher in CP‐C patien…

New clinical and pathophysiological perspectives defining the trajectory of cirrhosis

2021

Traditionally, the complications of cirrhosis, namely variceal bleeding, ascites and hepatic encephalopathy, were thought to result predominantly from circulatory dysfunction and altered organ perfusion arising as a result of portal hypertension. Over the past 20 years, large, international prospective studies have indicated the importance of systemic inflammation and organ immunopathology as additional determinants of organ dysfunction in cirrhosis, which not only manifests in the liver, brain, circulation and the kidneys, but also the immune system, gut, muscles, adrenal glands, reproductive organs, heart and lungs. This review provides an overview of the traditional and emerging concepts…

Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis

2013

Summary Background Propranolol is recommended for prophylaxis of variceal bleeding in cirrhosis. Carvedilol is a nonselective beta-blocker with a mild anti-alfa-1-adrenergic activity. Several studies have compared carvedilol and propranolol, yielding inconsistent results. Aim To perform a systematic review and meta-analysis of the randomised clinical trials comparing carvedilol with propranolol for hepatic vein pressure gradient reduction. Methods Studies were searched on the MEDLINE, EMBASE and Cochrane library databases up to November 2013. The weighted mean difference in percent hepatic vein pressure gradient reduction and the relative risk of failure to achieve a hemodynamic response (r…